| Literature DB >> 32393200 |
Lei Yang1, Xiaoxia Wu1, Ying Wang1, Chunfeng Wang1, Rong Hu2, Yong Wu3.
Abstract
BACKGROUND: Rehabilitation effects of exercise training on adults with chronic kidney disease (CKD) have been generally recognised; however, the effects of exercise training on proteinuria have been underexplored. Our aim was to explore the effects of exercise training on proteinuria in adult CKD patients without renal replacement therapy.Entities:
Keywords: Chronic; Exercise; Meta-analysis; Proteinuria; Renal efficiency
Year: 2020 PMID: 32393200 PMCID: PMC7216591 DOI: 10.1186/s12882-020-01816-7
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig. 1Flow diagram of the evaluation process
Characteristics of included studies
| Hellberg [ | RCT | E1: 73 | E1: CKD4–5 | E1: 67 ± 14 | E1: 28 ± 6 | E1: DM/Hypertension | E: YES | U-ACR (mg/mmol) | 0, 4, 8 mo |
| E2: 75 | E2: CKD4–5 | E2: 65 ± 14 | E2: 27 ± 5 | E2: DM/Hypertension | C: YES | ||||
| Liang [ | RCT | E1: 29 | E1: CKD2–3 | E1: 48.21 ± 3.62 | E1: 23.28 ± 2.49 | E1: Hypertension | E1: YES | 24 h UP (g/24 h) | 0, 12 w |
| E2: 29 | E2: CKD2–3 | E2: 48.50 ± 3.51 | E2: 23.3 ± 2.53 | E2: Hypertension | E2: YES | ||||
| C: 29 | C: CKD2–3 | C: 48.00 ± 3.62 | C: 23.25 ± 2.52 | C: Hypertension | C: YES | ||||
| Aoike [ | RCT | E1:12 | E1: CKD3–4 | E1: 56.0 ± 8.3 | E1: 31.1 ± 4.6 | E1: DM/Hypertension | E1: YES | Urinary protein (g/24 h) | 0, 12, 24 w |
| E2:13 | E2: CKD3–4 | E2: 56.3 ± 7.9 | E2: 31.8 ± 4.5 | E2: DM/Hypertension | E2: YES | ||||
| C:15 | C: CKD3–4 | C: 54.3 ± 8.7 | C: 30.7 ± 4.1 | C: DM/Hypertension | C: YES | ||||
| Leehey [ | Pilot RCT | E:7 | E: CKD2–4 | E: NG | E: NG | E: DM | E: YES | UPCR (mg/g). UACR (mg/g) | 0, 6, 24 w |
| C: 4 | C: CKD2–4 | C: NG | C: NG | C: DM | C: YES | Urine protein excretion (mg/24 h) | |||
| Hiraki [ | RCT | E: 14 | E: CKD3–4 | E: 69.0 ± 6.8 | E: 24.4 ± 3.5 | E: DM | E: NG | Urinary protein (g/gCr) | 0, 12 mo |
| C: 14 | C: CKD3–4 | C: 67.8 ± 6.9 | C: 23 ± 2.5 | C: DM | C: NG | ||||
| Leehey [ | RCT | E: 14 | E: CKD2–4 | E: 65.4 ± 8.7 | E: 36.2 ± 4.8 | E: DM2/Hypertension | E: YES | UPCR (mg/g) | 0, 3, 13 mo |
| C: 18 | C: CKD2–4 | C: 66.6 ± 7.5 | C: 37.4 ± 4.2 | C: DM2/Hypertension | C: YES | UACR (mg/g) | |||
| Pechter [ | Quasi-experimental study | E: 17 | E: moderate CKD | E: 52 (31–72) * | E: 29.4 ± 1.3 | E: Hypertension | E: NG | Urinary proteinuria excretion (U-Pro, g/24 h) | 0, 12 mo |
| C: 9 | C: moderate CKD | C: 48 (35–65) * | C: 28.1 ± 1.3 | C: Hypertension | C: NG | ||||
| Viana [ | Quasi-experimental study | E: 13 | E: CKD4–5 | E: 61 ± 8 | E: 26.6 ± 4.7 | E: NG | E: YES | UPCR (mg/mmol) | 0, 6 mo |
| C: 11 | C: CKD4–5 | C: 56 ± 16 | C: 29 ± 5.9 | C: NG | C: YES | ||||
| Nylen [ | Quasi-experimental study | E1: 38 | E1: CKD1–3 | E1: 62 ± 2.1 | E1: NG | E1: DM2, | E1: NG | urinary albuminuria (UAE, mg/g creatinine). | 0, 12 mo |
| E2: 53 | E2: CKD2 | E:2: 62.5 ± 7.4 | E2: NG | E2: DM2 | E2: NG | ||||
| E3: 37 | E3: CKD3 | E3: 63.8 ± 7.2 | E3: NG | E3: DM2 | E3: NG | ||||
| Hamada [ | A single-armed intervention study | E: 47 | E: CKD1–5 | E: 68.8 ± 11.8 | E: 25.3 ± 3.8 | E: DM | E: YES | Point of proteinuria: UPCR (g/gCr) | 0, 6 mo |
| Zhang [ | Quasi-experimental study | E: 25 | E: CKD2–3 | E: 36.36 ± 10.12 | E: NG | E: NG, | E: YES | Urinary proteinuria excretion (U-pro, mg/24 h) | 0, 3, 6 mo |
| C: 27 | C: CKD2–3 | C: 35.89 ± 9.64 | C: NG | C: NG | C: YES |
Notes. E: Experimental group; C: Control group; RCT: Randomized controlled studies; CKD: Chronic kidney disease; BMI: Body mass index; NG: Not given; Med use: Medication use; RAAS: Renin-angiotensin-aldosterone system drugs; DM: Diabetes mellitus; DM2: Type II diabetes; UACR: Urinary albumin-to-creatinine ratio; 24 h UP: 24-h urinary protein; UPCR: Urinary protein-to-creatinine ratio; mo: month; w: week; *: median and range
Exercise training parameters
| Hellberg [ | E1: ST + ET | ST: RPE 13–17 | ST: 90 min/w | 12 mo | ST: 3 times/w | HB /nearby gym | NO | YES |
| ET: Walking, running, cycling, and rowing etc. | ET: RPE 13–15 | ET: 30 min, 60 min/w | ET: 2 times/w | |||||
| (Vigorous) | ||||||||
| ST: Quadriceps extension, hamstrings curl, lats-pull down, etc. 2–3 sets of 10 repetitions. | ||||||||
| E2: BT + ET | ST: RPE 13–17 | BT: 90 min/w | 12 mo | BT: 3 times/w | ||||
| ET: The same to E1. | BT: RPE 13–17 | ET: 30 min, 60 min/w | ET: 2 times/w | |||||
| BT: Static and dynamic balance exercises (maintaining balance while standing with feet together, standing on one leg, etc.) 10 repetitions, 2–3 sets. | (Vigorous) | |||||||
| Liang [ | E1: AE | E1: 50% | AE: 30 min | 3 mo | 3 times/w | Unclear | Unclear | NO |
| 5 min warm up, ride a bike, 5 min of relaxation. | VO2peak RPE 12–13 (Moderate) | RE: 10 s/actions, 10 times/actions | ||||||
| E2: AE + RE | E2: 50% VO2peak | |||||||
| 5 min warm up, ride a bike plus thera-band resistance training. | RPE 12–13 | |||||||
| (Moderate) | ||||||||
| C: High quality and low protein (≤0.6 g/kg/d) and other reasonable diet, and routine treatment. | ||||||||
| Aoike [ | E1: HB AE AE: Walking. | E1: 40–60% VO2peak (Moderate) | AE: 30 min, Puls 10 min/4 w | 3 mo | 3 times/w | HB+ CB | YES | NO |
E2: CB AE AE: Walking on a treadmill. | E2: 40–60% VO2peak (Moderate) | |||||||
| C: Usual care | ||||||||
| Leehey [ | E: AE | E: 20–60% VO2peak | 30 min | 6 mo | 3 times/w | CB+ HB | YES (6 w) NO (18 w) (Mixed) | NO |
| AE: Walking on a treadmill. Warm-up, range-of-motion exercises, interval training, cool-down, and post-exercise range-of-motion exercises. | (Moderate) | Plus 5 min/2 w | ||||||
| C: Underwent the same testing battery but did not participate in any exercise training. | ||||||||
| Hiraki [ | E: AE + RE | E: RPE | AE: 30 min/8000 | 12 mo | 3 times/w | HB | NO | YES |
| AE: Walking. | (Moderate) | −10,000 steps | ||||||
| RE: Handgrip strengthening device squats and calf raises 20–30 repetitions per exercise. | RE: 20–30 min | |||||||
| C: Wore an accelerometer, but not given any exercise advice and continue the daily exercise. | ||||||||
| Leehey [ | E: AE + RE + diet (Nutritional counselling) | E: 25–84% VO2peak | AE: 60 min | 13 mo | 60 min/time- 3 times/w | HB | YES | NO |
| (Vigorous) | RE: 20–30 min | 30 min/time- 6 times/w | ||||||
| AE: Interval training on a treadmill. | HB (AE + RE): | |||||||
| RE: An elliptical trainer and cycle ergometer progressive resistance lower body exercise using elastic bands, hand-held weights or weight machine. | 30 min/time, or 60 min/time | |||||||
| C: Diet (Nutritional counselling). | ||||||||
| Pechter [ | E: AE | E: Low intensity | 30 min | 3 mo | 2 times/w | Unclear | Unclear | N0 |
| AE: Water-based, vertically in the pool with total immersion (water temperature, 24 °C), 10 min warm-up exercises with gradually increasing intensity, 10 min cooling-down exercise. | ||||||||
| C: Unclear | ||||||||
| Viana [ | E: AE | E: RPE 12–14 | 30 min | 6 mo | 5 times/w | HB | YES | NO |
| AE: walking. | (Moderate) | |||||||
| C: Usual physical activity. | ||||||||
| Nylen [ | E1: AE + RE | E1: 50–80% HRR | 60 min | 3 mo | Unclear | Unclear | YES | NO |
| AE + RE: 1 h session conclude that warm-up and cool-down and 30 min of combined aerobic and resistance training. | (Vigorous) | |||||||
| E2: The same to E1. | E2: 50–80% HRR | 60 min | 3 mo | Unclear | ||||
| (Vigorous) | ||||||||
| E3: The same to E1. | E3: 50–80% HRR | 60 min | 3 mo | Unclear | ||||
| (Vigorous) | ||||||||
| Hamada [ | E: AE + RE | RE: 3–4 METS | 90–120 min | 6 mo | 6 session/month | HB | Unclear | NO |
| AE + RE: Resistance and effective walking. | AE: 12–14 RPE | |||||||
| (Moderate) | ||||||||
| Zhang [ | E:AE + RE | IPAQ | 30 min | 6 mo | 3 times/w | HB | Unclear | NO |
| Regular walking, yoga, aerobic gymnastics, biking, etc. | (Vigorous) | |||||||
| One or more forms of the aerobic and resistance exercise items. | ||||||||
| C: Ordinary daily activities. | ||||||||
Notes. E Exercise group, C Control group, AE Aerobic exercise, RE Resistance exercise, w week, mo month, ST Strength training, BT Balance training, HB Home-based, CB Center-based, min minutes, HRR Heart rate reserve, ET Endurance training, RPE Rating of perceived exertion, METs Metabolic equivalent, VOpeak Peak oxygen uptake, IPAQ International Physical Activity Questionnaire. The intensity of classification about low, moderate, and vigorous according to the advice of ACSM [23]
Quality evaluation of quasi-experimental studies
| Quasi-experimental studies | |||||
|---|---|---|---|---|---|
| Items | Pechter [ | Viana [ | Nylen [ | Hamada [ | Zhang [ |
| 1 | Yes | Yes | Yes | Yes | Yes |
| 2 | Yes | Yes | Not applicable | Not applicable | Yes |
| 3 | Unclear | Yes | Yes | Yes | Unclear |
| 4 | Yes | Yes | Yes | Not applicable | Yes |
| 5 | No | No | No | No | Yes |
| 6 | Yes | Yes | Yes | Yes | Yes |
| 7 | Yes | Yes | Yes | Yes | Yes |
| 8 | Yes | Yes | Yes | Yes | Yes |
| 9 | Yes | Yes | Yes | Yes | Yes |
Notes. 1 Is it clear in the study what is the ‘cause’ and what is the ‘effect’ (i.e. there is no confusion about which variable comes first)? 2 Were the participants included in any comparisons similar? 3 Were the participants included in any comparisons receiving similar treatment/care, other than the exposure or intervention of interest? 4 Was there a control group? 5 Were there multiple measurements of the outcome both pre and post the intervention/exposure? 6 Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analysed? 7 Were the outcomes of participants included in any comparisons measured in the same way? 8 Were outcomes measured in a reliable way? 9 Was appropriate statistical analysis used?
Quality evaluation of randomised controlled trials
| Randomised controlled studies | ||||||
|---|---|---|---|---|---|---|
| Items | Hellberg [ | Liang [ | Aoike [ | Leehey [ | Hiraki [ | Leehey [ |
| 1 | Low | Low | Low | Low | Low | Low |
| 2 | Low | High | Unclear | Unclear | Unclear | Unclear |
| 3 | Low | High | Unclear | High | High | High |
| 4 | Low | Unclear | Unclear | Low | Low | Unclear |
| 5 | Low | Low | Low | Low | Low | High |
| 6 | Low | Low | Low | Low | Low | Low |
| 7 | Low | Low | Low | High | Low | High |
Notes. 1 Random sequence generation (selection bias); 2 Allocation concealment (selection bias); 3 Blinding of participants and personnel (performance bias); 4 Blinding of outcome assessment (detection bias); 5 Incomplete outcome data (attrition bias); 6 Selective outcome reporting? (reporting bias) 7 Other bias
Fig. 2Change in UACR, Exercise vs. Control. Notes. 95% CI, 95% confidence interval; SMD, standardized mean difference; UACR, urinary albumin-to-creatinine ratio
Fig. 3Change in UPCR, Exercise vs. Control. Notes. 95% CI, 95% confidence interval; SMD, standardized mean difference; UPCR, urinary protein-to-creatinine ratio
Fig. 4Change in 24 h UP, Exercise vs. Control. Notes. 95% CI, 95% confidence interval; SMD, standardized mean difference; 24 h UP, 24-h urinary protein
Fig. 5Change in 24 h UP, Before exercise vs. After exercise. Notes. 95% CI, 95% confidence interval; SMD, standardized mean difference; 24 h UP, 24-h urinary protein; AE, aerobic exercise; RE, resistance exercise
Fig. 6Change in UACR and UPCR, Before exercise vs. After exercise. Notes. 95% CI, 95% confidence interval; SMD, standardized mean difference; UPCR, urinary protein-to-creatinine ratio; UACR, urinary albumin-to-creatinine ratio